Summary of clinical outcomes
| . | From HSCT . | From first VAX* . |
|---|---|---|
| Follow-up time among survivors | ||
| Median (range), mo | 67 (60-81) | |
| 5-y OS (95% CI) | 39% (23-55) | 39% (23, 55) |
| 5-y PFS (95% CI) | 39% (23-55) | 39% (23-55) |
| 2-y cumulative incidence of relapse (95% CI) | 48% (30-64) | |
| 2-y cumulative incidence of NRM (95% CI) | 9% (2.2-22) | |
| 180-d cumulative incidence of grade 2-4 aGVHD (95% CI) | 24% (11-40) | |
| 2-y cumulative incidence of cGVHD relapse (95% CI) | 33% (17-50) |
| . | From HSCT . | From first VAX* . |
|---|---|---|
| Follow-up time among survivors | ||
| Median (range), mo | 67 (60-81) | |
| 5-y OS (95% CI) | 39% (23-55) | 39% (23, 55) |
| 5-y PFS (95% CI) | 39% (23-55) | 39% (23-55) |
| 2-y cumulative incidence of relapse (95% CI) | 48% (30-64) | |
| 2-y cumulative incidence of NRM (95% CI) | 9% (2.2-22) | |
| 180-d cumulative incidence of grade 2-4 aGVHD (95% CI) | 24% (11-40) | |
| 2-y cumulative incidence of cGVHD relapse (95% CI) | 33% (17-50) |
VAX, vaccination.
Median time from HSCT day 0 to VAX 1 = 35 d.